Some studies showed that activation of CD200R, either by binding of the ligand CD200 or through treatment with an agonistic antibody, leads to inhibition of tumour-associated myeloid cells (TAMCs), ultimately reducing tumour burden [13, 14]. The gene discussed is CD200R1; the disease is neoplasm.